Phase II trial of PD-L1-CAR-NK cell immunotherapy, in combination with an IL-15 agonist (N-803) and pembrolizumab (NCT04847466), is currently underway among patients with head and neck cancers and gastric cancers in the United States. Here, CD274 is linked to head and neck cancer.